Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.
Researchers in Japan and Australia say they have made important progress in developing a blood test that could in future help doctors detect who might go on to get Alzheimer’s disease.
Pfizer released an update of the company’s pipeline, including eight different discontinued projects in the field of neuroscience.
Eisai and Boston University School of Medicine Announce Research Collaboration to Study the Effects of Alzheimer’s Disease-associated Genetic Variants on Brain
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia.
Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.
During a fireside chat at BIO International in San Diego in summer 2017, Daniel Skovronsky – now president of Lilly Research Labs – confirmed Eli Lilly’s commitment to finding an effective therapy for Alzheimer’s disease. Lilly continues to push forward. EP Vantage highlighted and analyzed the company’s five Phase I programs for Alzheimer’s disease. Much like what Skovronsky said about learning from the Phase III solanezumab failure, EP Vantage pointed to some of the hopes the Lilly programs have for blocking the development of amyloid plaques.
After terminating 485 positions linked to its failed Alzheimer’s therapy solanezumab, Lilly aims to terminate another 3 percent of R&D staff, Endpoints reported.